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Type B Coxsackieviruses (CVBs) belong to the enterovirus genus, and they cause both acute and chronic
diseases in humans. CVB infections usually lead to flu-like symptoms but can also result in more serious
diseases such as myocarditis, aseptic meningitis and life-threatening multi-organ infections in young
infants. Thus, CVBs have long been considered as important targets of future vaccines.
We have previously observed CVB1 capsid disintegration and virus concentration decrease with 12-day
long formalin inactivation protocol. Here a scalable ion exchange chromatography purification method
was developed, and purified CVB1 was inactivated with UV-C or formalin. Virus morphology and concen-
tration remained unchanged, when the UV (2 min) or formalin (5 days) inactivation were performed in
the presence of tween80 detergent. The concentration of the native and UV inactivated CVB1 remained
constant at 4 C during a six months stability study, whereas the concentration of the formalin inacti-
vated vaccine decreased 29% during this time. UV treatment decreased, whereas formalin treatment
increased the thermal stability of the capsid.
The formalin inactivated CVB1 vaccine was more immunogenic than the UV inactivated vaccine; the
protective neutralizing antibody levels were higher in mice immunized with formalin inactivated vac-
cine. High levels of CVB1 neutralizing antibodies as well as IgG1 antibodies were detected in mice that
were protected against viremia induced by experimental CVB1 infection.
In conclusion, this study describes a scalable ion exchange chromatography purification method and
optimized 5-day long formalin inactivation method that preserves CVB1 capsid structure and immuno-
genicity. Formalin treatment stabilizes the virus particle at elevated temperatures, and the formalin inac-
tivated vaccine induces high levels of serum IgG1 antibodies (Th2 type response) and protective levels of
neutralizing antibodies. Formalin inactivated CVB vaccines are promising candidates for human clinical
trials.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Coxsackievirus B1 (CVB1) is a RNA virus belonging to the picor-
naviridae family and the enterovirus genus. Infections caused by
the six Coxsackievirus B types are usually asymptomatic or lead
to flu-like symptoms. However, they can also result in serious dis-eases such as myocarditis [1], aseptic meningitis [2], pancreatitis
[3] and life-threatening multi-organ infections in young infants
[4]. In fact, CVBs have constantly been among those 15 entero-
viruses most commonly reported to CDC by diagnostic laboratories
in US causing significant morbidity especially among young chil-
dren [5]. In addition, CVBs have been linked to chronic diseases
such as cardiomyopathies and type 1 diabetes [6–8]. Thus, CVBs
have long been considered as potential targets of future entero-
virus vaccines [9–11].
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there are no clinically approved treatments or vaccines available
against enteroviruses. To meet the need for preventing CVB associ-
ated diseases the clinical development of a vaccine against T1D
associated CVB serotypes has recently started [7]. With this comes
an increasing demand for improved CVB vaccine production meth-
ods allowing for large scale vaccine production.
We have previously developed optimized production and
purification methods for CVB1, CVB6 [14,15] and CVB3 [16] viruses
and formulated the purified viruses as formalin inactivated whole
virus vaccines. These vaccines induced robust neutralizing anti-
body responses in mice and the CVB1 vaccines were shown to pro-
tect against both CVB1 infection and CVB1 induced diabetes in
mouse models [14,15]. We have shown previously that a 12-day
formalin inactivation period negatively affects the virus structure
and concentration [14]. Therefore, we have used 254 nm ultravio-
let (UV) light irradiation as an alternative virus inactivation
method and studied the effects of the inactivation methods on
the stability, integrity and immunogenicity of the viruses.
In the present study, a scalable ion exchange chromatography
purification method and optimized 5-day long formalin inactiva-
tion method for CVB1 was developed. Virus morphology and con-
centration remained unchanged when UV or formalin inactivation
was performed in the presence of tween80 detergent and as such,
the length of formalin inactivation was decreased to five days from
twelve days. The formalin treated particles were more resistant to
elevated temperatures than the native or UV treated particles, pro-
viding stability at elevated temperatures by inhibiting the initial
heat-induced capsid expansion. Here we also demonstrate, that
the formalin inactivated CVB1 vaccine is more immunogenic than
the UV inactivated CVB1 vaccine. The protective neutralizing anti-
body levels were higher and persisted for longer in mice immu-
nized with formalin inactivated CVB1 vaccine.2. Materials and methods
2.1. Virus production and purification
A wild CVB1 field isolate from Finland (kindly provided by Vac-
tech Ltd.) was used and produced in Vero cells as described previ-
ously [14]. Virus particles were concentrated by pelleting through
a 30% sucrose cushion using ultracentrifugation (175 000 g, 16 h at
4 C). Pelleted virus was further purified with ion exchange chro-
matography using a strong AEX monolithic column (6.7 mM
ID  4.2 mM, V: 1 ml) from BIA Separations (Ljubljana, Slovenia)
with quaternary amine (QA) chemistry as described previously
[16]. The only exception was that the purification was done in
the presence of 0.1% tween80 detergent. Purified viruses were
characterized as described previously [14].2.2. Vaccine production and characterization
Purified viruses were inactivated in 0.01% (vol/vol) formalin for
5 days at 37 C or by UV-C irradiation at 254 nm (2.0 mWatts/cm2)
for 2 min in M199-0.1% tween80. The inactivation was confirmed
by demonstrating the lack of infectious virus in green monkey kid-
ney cells in TCID50 end-point dilution assay as described earlier
[14]. The vaccine was formulated in M199 medium containing
0.1% tween80 to contain 1 mg inactivated CVB1 per vaccine dose.
Transmission electron microscopy (TEM) analysis of the vacci-
nes was performed as described previously [14]. Dynamic light
scattering (DLS) analysis was performed with a Zetasizer Nano ZS
instrument (Malvern Instruments Ltd.). The hydrodynamic diame-
ter of viruses was determined as the average of three measure-ments (each measurement containing 10–20  10 s datasets at
25 C). Total protein concentration measurement (Pierce BCA
assay), SDS-PAGE and Western blot analyses were performed as
described previously [14].
The thermal stability of the virus particles was characterized by
a thermofluorometric dye-binding assay using the protein binding
dye SYPRO orange (Invitrogen) and the nucleic acid binding dye
Midori Green (Nippon Genetics). Reaction mixtures of 25 ml con-
taining 4.0 mg CVB1, 6  SYPRO orange or 10 Midori Green with
PBS were mixed and heated from 25 to 110 C, with fluorescence
reads taken at 1 C intervals every 30 s within the Biorad quantita-
tive PCR system. SYPRO Orange, a fluorescence dye that binds to
the hydrophobic amino acid residues, was used to analyse the
unfolding or denaturation of the capsid proteins to study the con-
formational stability of the viruses. The fluorescence intensity of
the dye in the presence of viruses was plotted as a function of
the temperature, and melting temperatures (Tm) of the viruses
were derived from the inflection points of the transition curve
using the Boltzmann equation [17]. The melting temperature at
which the genome of virus becomes accessible (TRNA), was deter-
mined from the fluorogram of Midori Green.2.3. Mouse immunizations and CVB1-challenge
C57BL/6J mice were housed in specific pathogen-free conditions
at Karolinska Institutet, Stockholm, Sweden. All experiments were
conducted in accordance with the NIH Principles of Laboratory
Animal Care and national laws in Sweden and were approved by
the local ethics committee. Two vaccination experiments were per-
formed. C57BL/6J mice were vaccinated interscapularly (i.s.) on
days 0, 21 and 35 with 1 mg of UV or formalin inactivated CVB1
(n = 5 / experiment). In the second vaccination experiment mice
were challenged with 1  106 plaque forming units (PFU) CVB1
(intraperitoneal injection; i.p.) on day 60 as described earlier [15].2.4. Neutralization assays and CVB1 specific ELISA
Neutralizing antibodies against CVB1 were measured by stan-
dard virus plaque reduction assay in green monkey kidney
(GMK) cells as previously described [6]. Sera from C57BL/6J CVB1
vaccinated mice was tested for CVB1 specific IgG and IgG subtype
antibodies by ELISA according to the previously described proce-
dures [18]. Briefly, 96-well half-area polystyrene plates (Corning
Inc., Corning, NY) were coated with 50 ng of CVB1 virus-like parti-
cles (CVB1-VLPs) per well. CVB1-VLPs were produced with insect-
cell baculovirus expression system and were concentrated from
the culture supernatant by tangential flow filtration and were puri-
fied with the combination of anion and cation exchange chro-
matography steps (Hankaniemi et al, manuscript submitted).
Antibodies were detected with horseradish peroxidase-
conjugated anti-mouse IgG (Sigma-Aldrich, St. Louis, MO), IgG1
(Invitrogen) or IgG2a (Invitrogen) and SIGMA FAST OPD substrate
(Sigma-Aldrich). Optical densities (OD) at 490 nm were measured
by Victor2 microplate reader (PerkinElmer).2.5. Statistical analyses
All statistical analyses were performed using GraphPad Prism
version 5.02. Neutralizing antibody titers and CVB1-specific anti-
body responses were analysed with Mann-Whitney U test. Plaque
assay virus titrations were analysed by Kruskal-Wallis test.
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3.1. Ion-exchange purification yields a highly pure CVB1
CVB1 was produced in Vero-cells and the virus was concen-
trated and partially purified from the clarified cell culture super-
natants by 30% sucrose cushion pelleting. In our previous study
we discovered that tween80-detergent increases the virus yield
and stability [14]. Therefore, the virus was further purified with
anion exchange chromatography (AEX) in the presence of 0.1%
tween80, which was also compatible with the chromatography.
CVB1 virus was eluted from the AEX-column at 60 mM NaCl
(Fig. 1a). SDS-PAGE analysis and subsequent detection of proteins
with stainfree staining method revealed protein bands of approxi-
mately 31 kDa and 26 kDa that corresponded with the CVB1 capsid
proteins VP1 and VP3 [14]. The purity of the virus was >95% as
measured by densitometric analysis of SDS-PAGE gel (Fig. 1b, mid-
dle panel). Viral VP1 capsid protein was also detected by Western
blotting using a mouse anti-enterovirus mAb (clone 5-D8/1, DAKO)
(Fig. 1b, right panel). According to the TEM images, the particles
were intact and had the expected morphology with an average
diameter of 30 nm (Fig. 1c).Fig. 1. Characterization of chromatography purified CVB1 virus. (A) CVB1 virus
concentrated by 30% sucrose pelleting, was loaded onto an anion exchange column.
The bound virus and impurities were eluted from the column with the combination
of stepwise and linear gradients. Grey area marks the elution peak of CVB1. (B) SDS-
PAGE and Western blot analyses of the purified viruses. Middle panel shows the
total protein stained CVB1 preparation and the right panel the VP1 protein stained
with 5-D8/1 mAb. (C) TEM image of the purified CVB1 virus. Bar: 100 nm. Image
captured from 25000 magnification.3.2. Optimization of the CVB1 inactivation methods and evaluation of
the conformational stability of the native, UV and formalin treated
viruses
We have previously shown that formalin inactivation of CVB1
negatively affects the virus preparations [14]. Here, we evaluated
whether a shorter duration of the formalin inactivation period
and a different virus buffer composition could lead to better
preservation of the virus integrity. We also explored the inactiva-
tion of the virus using potentially less harsh inactivation method,
UV-C irradiation, and examined the effect of the different protocols
on CVB1 morphology, stability, particle size, particle size distribu-
tion and concentration. To this end, CVB1 virus was formalin inac-
tivated (5 days in 0.01% formalin at 37 C) or UV irradiated (2 min
with intensity of 2.0 mWatts/cm2) followed by analyses by Trans-
mission Electron Microscopy (TEM), Dynamic Light Scattering
(DLS) and SDS-PAGE. Inactivation was done in the presence of
0.1% tween80 detergent for all protocols. The previously observed
virus capsid disintegration and decrease of the virus concentration
[14] was avoided when the UV or formalin inactivation was per-
formed in the presence of tween80 detergent. According to TEM,
we found three virus forms with differential staining patterns
(Fig. 2a–c, Supplementary Fig. 1). All samples represented
30 nm capsids with the correct icosahedral morphology. We sug-
gest that the viruses which were impermeable to uranyl acetate
stain represent solid capsids, partly permeable viruses represent
slightly porous capsids, whereas fully permeable viruses represent
very porous capsids. The native (Fig. 2a) and UV inactivated
(Fig. 2b) viruses contained similar proportions of impermeable
(75%) as well as partly permeable (25%) particles (Supplementary
Fig. 1a and b). Formalin inactivated (Fig. 2c) virus preparations
were composed of 60% of particles that were fully permeable to
the stain and 40% of particles that were partly permeable to the
stain (Supplementary Fig. 1c). These results differed considerably
from those with the native and UV inactivated viruses and indicate
that formalin treatment appears to induce capsid porosity.
The stability of the native and differentially treated CVB1
viruses was analysed by monitoring changes in particle size distri-
bution by DLS. All CVB1 vaccines (that originated from the same
CVB1 stock) were stored at 4 C in M199-tween80 for six months
and were analysed by DLS on day 0 and at the end of the six-
month storage period. The samples were gently mixed beforeDLS analyses to obtain a representative sample and avoid exclusion
of particles that may have sedimented during storage. Native CVB1
virus contained 79% 37 nm particles (Scattering Intensity (SI)
63,689 kcps) on day 0 and 67% 43 nm particles (SI 101,335 kcps)
after six months storage at 4 C (Fig. 2d). UV inactivated CVB1 con-
tained 76% 41 nm particles (SI 64,499 kcps) on day 0 and 66%
44 nm particles (SI 98,024 kcps) after six months storage at 4 C
(Fig. 2e). Formalin inactivated CVB1 contained 58% 43 nm particles
(SI 81,161 kcps) on day 0 and 28% 49 nm particles (SI 107,935 kcps)
after six months storage at 4 C (Fig. 2f). During the six months
storage period, the volume of 40 nm particle population
decreased (Fig. 2g), whereas the mean sizes of the different particle
populations were found to increase slightly (Fig. 2h). Inspection of
the intensity-based particle size distribution revealed increases in
the scattering originating from particles with diameter >1 mm.
These results indicate that during storage, a portion of the virus
samples became insoluble. This effect was most notable in the case
of the formalin inactivated particles (Fig. 2f). In comparison, the
native and UV inactivated viruses were relatively stable when
stored at 4 C for six months (Fig. 2d,e).
Concentration of the differentially formulated CVB1 vaccines
was also assessed after six months storage at 4 C by densitometric
analysis. Equal volumes of the vaccines (stored at 4 C in M199-
tween80 for six months) from both day 0 and the month 6 time
point were run on a SDS-PAGE gel and proteins were detected with
a stainfree staining method. Based on densitometric analysis of the
Fig. 2. Stability profiles of native CVB1 virus, UV and formalin inactivated CVB1 vaccines. TEM analysis of chromatography purified (A) native, (B) UV inactivated and (C)
formalin inactivated CVB1 virus. Scale bars 100 nm. (D-H) CVB1 viruses formulated in the vaccine buffer (M199-0.1% tween80) stored at 4 C for 0 and six months were
analysed by dynamic light scattering (DLS) for their size and volume distributions: (D) Native CVB1, (E) UV inactivated CVB1 and (F) Formalin inactivated CVB1. (G) The
volume of 40 nm particle population at day 0 and after 6 months storage period for the different CVB1s. (H) The size of the particles at day 0 and after 6 months storage
period for the different CVB1s. (I) SDS-PAGE analysis of the native CVB1 virus and CVB1 vaccines from day 0 and after storing at 4 C for 6 months. Two mg of virus or vaccine
were loaded per well.
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UV inactivated vaccine did not change during the six months stor-
age period (Fig. 2i). Two prominent proteins of approximately
31 kDa and 26 kDa corresponding to the CVB1 capsid proteins
VP1 and VP3 were detected in the vaccines by total protein stain-
ing (Fig. 2i). However, the concentration of the soluble formalin
inactivated CVB1 vaccine decreased by 29% during the 6 months
storage period. These results show that virus morphology and pro-
tein concentrations remained relatively stable when the native
virus or UV inactivated virus was stored in M199 medium in the
presence of tween80 detergent. However, storage at 20 C or
lower temperatures might be advisable for the long-term storage
of formalin inactivated CVB1 which decreased in concentration at
4 C. To find out if storage at 4 C affects the immunogenicity of
the vaccine, separate studies should be performed.3.3. Thermal stability of native CVB1, UV and formalin inactivated
CVB1 vaccines
Desired vaccine candidates are stable during storage, especially
at elevated temperatures. Polioviruses have been shown to
undergo antigenic switch from the native (N- or D-antigenic) form
to a non-native or heated (H- or C-antigenic) form when heated
above 50 C [19]. The latter form (H- or C-antigenic) is not able
to elicit a robust neutralizing antibody response and as such, there
must be a constant amount of poliovirus D-antigen in formalin
inactivated poliovirus vaccines to maintain immunogenicity [20].
Due to the influence of temperature on vaccine stability, the ability
of the native, UV or formalin inactivated CVB1 preparations were
evaluated by Differential Scanning Fluorimetry (DSF). Two fluores-
cent dyes were employed in the assay: SYPRO Orange, a fluores-
cence dye that binds to hydrophobic amino acid residues,
indicating unfolding or denaturation of the capsid proteins and
Midori Green, a fluorescence dye that binds to the nucleic acid,
indicating the access to the viral RNA. The fluorescence intensity
of the respective dyes in the presence of virus was plotted as a
function of the temperature, and melting temperatures (Tm) of
the viruses were derived from the inflection points of the transition
curve using the Boltzmann equation [17]. SYPRO orange had two
peaks in the fluorogram (Fig. 3a), where Tm1 indicated capsid
expansion and the exposure of hydrophobic residues, whereas
Tm2 indicated denaturation of the viruses [21] (Fig. 3b). The virus
melting temperatures differed between the differentially treated
CVB1 viruses. According to Tm1 values, formalin treated particles
were more resistant to elevations in the temperature during the
initial temperature induced unfolding event than the native virus.
Contrastingly, the UV treated particles were less resistant than the
native virus in the same conditions. The Tm2 data indicated that UV
treated particles were also less resistant to elevations in tempera-
ture up to the final denaturation temperature (Fig. 3b).
The melting temperature (TRNA) at which the genome of UV
inactivated, native and formalin inactivated CVB1 becomes acces-
sible to fluorescent dye, was determined with DSF (Fig. 3c). TRNA
(Fig. 3d) was higher than Tm1 and lower than Tm2 (Fig. 3b) in all
of the vaccine preparations. The increase in Tm1 seen in the forma-
lin inactivated CVB1 virus was matched by an increase in TRNA,
whereas the decrease in the Tm1 value for the UV inactivated
CVB1 did not alter the TRNA. This observation could be explained
by the fact that as the thermal stability of CVB1 increases, alter-
ations in the capsid are delayed and as such the accessibility of
RNA which is synchronized with the initial unfolding of the capsid,
is altered. In conclusion, the results from the thermal stability
assay employed here (Tm1 and TRNA results), formalin treatment
protected the virus against temperature induced capsid expansion.3.4. UV and formalin inactivated CVB1 vaccines are immunogenic and
protect against viremia following infection with CVB1
No information is available on whether the different CVB inac-
tivation methods during the vaccine production process affect the
vaccine immunogenicity. Therefore, the immunogenicity of the UV
and formalin inactivated CVB1 vaccines was tested in C57BL/6J
mice following the experimental timeline shown in Fig. 4a. Sera
from CVB1 vaccinated mice were evaluated for CVB1 neutralizing
ability in vitro (n = 10). All vaccinated mice had already generated
neutralizing antibodies by day 21 (after one vaccination) (Fig. 4b).
Neutralizing geometric mean titers (GMTs) were 338 and 446 at
day 21 for mice immunized with the UV and formalin inactivated
CVB1 vaccines respectively. After three immunisations (on day
49) the neutralizing GMT was 891 for the UV inactivated CVB1 vac-
cine and 3104 for the formalin inactivated CVB1 vaccine. The neu-
tralizing antibody response was stronger in the mice that were
immunized with formalin inactivated CVB1 vaccine on days 42,
49 and 60 (after three immunisations) compared to the animals
that were immunized with UV inactivated CVB1 vaccine (Mann-
Whitney U test, p = 0.026, 0.031 and 0.019 respectively) (Fig. 4b).
In the second vaccination experiment the neutralizing antibody
levels were followed until day 60. Neutralizing antibody GMTs in
sera from UV inactivated CVB1 vaccinated mice decreased from
776 to 256 between day 49 and day 60 and the same values chan-
ged from 7132 to 5405 in mice immunized with formalin inacti-
vated CVB1 vaccine (Fig. 4b). Mice were infected with CVB1 on
day 60 to establish whether the vaccines would prevent viremia
in the blood on day 3p.i. or virus replication in the heart and pan-
creas on day 5p.i., viral titers are expressed as PFU/ml of blood or
PFU/mg of tissue. All mice immunized with formalin inactivated
CVB1 vaccine (5/5) were protected against viremia (Fig. 4c) and
no replicating virus was detected in their pancreas (p = 0.0093)
(Fig. 4d) or heart (Fig. 4e). In contrast, only 2/5 mice immunized
with UV inactivated CVB1 vaccine were protected against viremia
as determined by standard plaque assay analysis of the blood sam-
pled on day 3p.i. (Fig. 4c). Moreover, replicating virus was not
detected in the pancreas of the two mice without viremia on day
3p.i. whereas the remaining 3/5 UV inactivated CVB1 vaccinated
mice had replicating virus in their pancreas (Fig. 4d). All buffer
treated mice had replicating virus in the pancreas on day 5p.i.
(Fig. 4d), 4/5 mice were viremic on day 3p.i. (Fig. 4c) and 3/5 had
replicating virus in the heart (Fig. 4e). Overall, vaccination with for-
malin treated virus provided more efficient protection against
infection as compared to that obtained with UV treated virus.
3.5. CVB1 vaccination results in an IgG1 oriented immune response
Sera of C57BL/6J mice immunized with UV or formalin inacti-
vated CVB1 vaccines or control vaccine buffer treated mice were
analysed for CVB1-specific serum IgG, IgG1 and IgG2a 49 days after
the prime vaccination. All immunizedmice were positive for CVB1-
specific IgG by ELISA which was not found in the control animals.
The magnitude of the IgG response was high in both groups. GMTs
were 11,143 and 6400 in the groups receiving UV and formalin
inactivated vaccines respectively (Fig. 5a). However, no statistically
significant difference (Mann-Whitney U test, p = 0.58) was
observed in the magnitude of IgG responses induced by the UV
or formalin inactivated vaccines. CVB1-specific IgG1 and IgG2a
immunoglobulin subtypes which are indicators of Th2 and Th1
type immune responses were also investigated. Both vaccines
induced a strong Th2-type (IgG1) response (GMTs were 1600 and
3676 respectively in the groups receiving UV and formalin inacti-
vated vaccines), whereas the Th1-type (IgG2a) responses were very
low in both groups (Fig. 5b). Similar to IgG responses, no significant
differences (Mann-Whitney U test) were observed in the magni-
Fig. 3. Thermal stability profile of UV inactivated, native and formalin inactivated CVB1-vaccines. UV inactivated, native and formalin inactivated CVB1 virus were analysed
with Differential Scanning Fluorometric assays using SYPRO orange protein binding dye and Midori green nucleic acid-binding dye. (A) Relative fluorescence of SYPRO orange
and (B) melting temperatures (Tm1 and Tm2) of different CVB1 preparations determined from fluorogram. (C) Relative fluorescence of Midori green and (D) the dye
accessibility temperature for RNA (TRNA) of different CVB1 preparations determined from fluorogram.
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UV or formalin inactivated vaccines.
4. Discussion
In this study, our objective was to optimize the purification, for-
mulation and inactivation of CVB1 to produce stable and immuno-
genic inactivated virus vaccines. We also wanted to investigate the
extent to which UV and formalin inactivation treatments affected
the virus stability and immunogenicity.
In our previous study we developed a scalable three-step purifi-
cation method for the production of a CVB1 vaccine, which relied
on 30% sucrose cushion pelleting, gelatin affinity chromatography
and 30/50% sucrose cushion pelleting [14]. Although the method
can be scaled up to purify several litres of virus containing super-
natant, the method developed in the current study is more suitable
for industrial scale purification, because it consists of only two
steps (30% sucrose cushion pelleting and AEX). We showed previ-
ously that the addition of tween80 detergent in the purification
process increases virus yield and stability [14] and as such this
detergent was included in all the steps of the purification process.
Inactivation with formalin is commonly used to produce com-
mercial human virus vaccines such as those against polio [22]. For-
malin has an effect on both genome and proteins. It acts as an
alkylating agent by crosslinking RNA to capsid proteins, causing a
block to genome reading, and also as crosslinker by formation of
inter- and intra-molecular methylene bridges between primary
amino groups. [23] We have shown previously that the 12 day for-
malin inactivation protocol used for the inactivation of poliovirus
vaccine [22] causes a dramatic change in CVB1 integrity and that
95% of the CVB1 virus particles dispersed into smaller units fol-
lowing inactivation [14]. Therefore, in the current study, we have
examined whether UV irradiation could serve as an alternative
inactivation method and addressed whether decreasing the forma-
lin inactivation length from 12 to five days would prevent the par-
ticle disintegration. Based on wavelength, UV light can besubdivided into three classifications: UV-A (320–400 nm), UV-B
(280–320 nm) and UV-C (200–280 nm). UV-C can lead to forma-
tion of dimers between two adjacent pyrimidines (uracil and thy-
mine). Formation of pyrimidine dimers can put a strain on the
sugar backbone of the genome, which possibly leads to breaks in
the genome [23]. UV-C may also crosslink proteins [24] and induce
crosslinking between nucleic acids and proteins [25]. Here, a com-
parative study on the effects of 254-nm UV-C inactivation and 5-
day long formalin inactivation on CVB1 was performed. Shorter
formalin inactivation (3–5 days) periods have been utilized with
other enterovirus vaccines including EV71 [26] and CAV vaccines
(serotypes 6, 10 and 16) [27]. Also, UV inactivation has been used
in the inactivation of EV71 and polio vaccines [26,28,29]. In the
present study, we show that when UV or formalin inactivation
was performed in the presence of tween80-detergent and the
length of formalin inactivation was decreased to five days (instead
of the 12 day inactivation protocol employed previously [14]),
virus morphology was preserved, and the virus concentration
remained unchanged when measured immediately after the inac-
tivation period, highlighting the improvement in the methodology.
Although the TEM analysis showed that the diameters of the
native, UV and formalin inactivated viruses were approximately
30 nm with icosahedral symmetry (characteristic to entero-
viruses [16]), the physical appearance of the formalin inactivated
virus was different to native and UV inactivated viruses. Approxi-
mately 60% of the formalin-inactivated viruses exhibited a ring-
like appearance due to stain incorporation into capsids, suggesting
that formalin treatment caused physical changes to the virus
resulting in capsid porosity.
An important and desirable feature of a vaccine is stability dur-
ing storage, especially at elevated temperatures. Some virus vacci-
nes, such as inactivated poliovirus vaccines (IPVs) are temperature
sensitive and require storage between 2 C and 8 C, whereas oral
poliovirus vaccine (OPV) requires storage at20 C [30]. In the cur-
rent study we show that the concentration of native CVB1 virus or
UV inactivated CVB1 vaccine did not change during the six months
Fig. 4. UV and formalin inactivated CVB1 vaccines induce neutralizing antibody responses and protect against viremia following infection with CVB1 in C57BL/6J mice. (A)
Schematic showing the experimental timeline of the immunisation strategy in C57BL/6J mice. The immunogenicity of the UV or formalin inactivated CVB1 was tested by
injecting 3  1 mg non-adjuvanted vaccine i.s. to five mice in two separate experiments (n = 5 + 5). (B) CVB1 neutralizing antibody titers in the sera of mice immunized with
CVB1 vaccines in samples taken days 21, 35, 42, 49 (n = 10) and 60 days (n = 5) after the prime vaccination. Mean neutralizing antibody titers are indicated by the line ± SEM;
* = p < 0.05, compared to the other differentially formulated vaccines at each time point, as determined by Mann-Whitney U test. The dotted line represents the protective
neutralizing antibody threshold (dilution 1024) and vaccinated mice at or above this level were protected against viremia (following infection with CVB1). (C) Cytopathic
virus measured in the (C) blood, (D) pancreas and (E) heart of the buffer-treated (n = 5) or vaccinated (n = 5) mice on day 3 p.i. by standard plaque assay. Mean values ± SEM,
**p < 0.01, Kruskal-Wallis test.
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vated CVB1 vaccine decreased by approximately 29% during the
6 months storage period at 4 C. The latter vaccine was produced
by inactivation with 0.01% formalin, formulated in M199-0.1%
tween80 and because the initial formalin concentration in the
inactivation process was relatively low, we decided not to neutral-
ize the formalin after the 5-day inactivation period which may
account in part for the decrease seen in the vaccine concentration.
Furthermore, M199 contains components reacting with formalin,which should prevent further chemical crosslinking during
extended storage. However, we observed decreased solubility for
the formalin inactivated virus during the six months stability study
that might have been caused by some reactive formalin present in
the vaccine. In line with our results with UV inactivated and native
CVB1, an EV71 VLP vaccine remained stable for at least five months
storage in appropriate buffers [31]. A number of determinants that
have capsid stabilising properties, such as stabilizing compounds
[32] and amino acid substitutions [21] have been previously
Fig. 5. CVB1-specific serum IgG-, IgG1- and IgG2a-antibody responses. Mean end-point titration curves of anti-CVB1 (A) total IgG, (B) IgG1 and IgG2a antibodies in the sera of
C57BL/6J mice vaccinated with UV or formalin inactivated CVB1 vaccines. Sera was collected on day 49 after the prime vaccination for each group. Mean titration curves with
standard errors of the mean of the experimental groups are shown (n = 5). The positivity cut-off OD value was 0.1 (control mice mean OD + 3  SD).
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(V87A and I194V) have been identified which enhance virus stabil-
ity by preventing premature uncoating and the release of viral RNA
at high temperatures [21]. In the current study we measured the
capsid flexibility and denaturation temperature of the native and
inactivated CVB1 preparations under continuously increasing ther-
mal stress in a DSF-assay. We found that formalin treated particles
were more resistant to temperature induced unfolding than the
native particles, whereas the inverse was true for the UV treated
particles. Although TEM analysis showed that all of the formalin
inactivated particles were partially or completely permeable to
the negative stain (which could be a sign of structural instability),
we found that they were even more thermostable than the native
or UV inactivated viruses. This demonstrates that formalin treat-
ment can be used for the production of stabilized vaccine
candidates.
Immunity to CVB is serotype-specific and the pathogenesis of
the infection is not fully understood [33]. CVB infections induce
rapid and strong neutralizing antibody responses. First IgM anti-
bodies appear after 7–10 days in both humans [34] and mice
[35], followed by the IgG antibodies. Neutralizing antibodies (anti-
bodies mainly directed toward the CVB capsid proteins VP1, VP2
and VP3) approximately appear from the second week of infection
and immunity may be life-long. [36] Thus, the most important fea-
ture of a CVB vaccine is the generation of long lasting protective
levels of neutralizing antibodies. The loss of viral antigenicity has
been observed in UV inactivated poliovirus showing both antigenic
and morphologic change [28,29]. Formalin inactivation has been
shown to alter the antigenicity of poliovirus through the modifica-
tion of antigenic sites and the effects on different epitopes varied
[28]. During the second immunization experiment in the current
study, the neutralizing antibody levels were followed for 60 days
and the mice were challenged thereafter. A significant difference
in the level and longevity of the antibody response was found
between the two vaccines. During day 49 and 60, the neutralizing
GMTs decreased from 776 to 256 for the mice immunized with UV
inactivated vaccine and from 7132 to 5405 for the mice immunized
with formalin inactivated vaccine. The challenge virus dose (106
PFU) was optimized to ensure that a systemic infection was
obtained, and the mice were immunized with relatively low dose
of each vaccine (1 mg, respectively) to enable the detection of pos-
sible differences in the immunogenicity of the vaccines. We found
that the protective neutralizing antibody level was 1024 for this
dose of virus in C57BL/6J mice. All five mice immunized with for-
malin inactivated virus were protected against CVB1 challenge,
whereas only 2/5 of the mice immunized with UV inactivated viruswere protected. 3/5 of the mice immunized with UV inactivated
virus had neutralizing antibody titer lower than 1024 and these
mice were not protected from viremia. This suggests that sufficient
amounts of neutralizing antibodies are necessary to induce the
main protective mechanism against enteroviruses. We hypothesise
that the virus epitopes that induce the neutralizing antibodies and
result in protective immunity against CVB1 might be better con-
served when the virus is inactivated with formalin. Alternatively,
we hypothesise that the capsid proteins and virus genome chemi-
cally modified by formalin act like adjuvants to trigger a stronger
immune response. Moreover, a further explanation could be that
the UV inactivated virus induces more antibodies that do not have
neutralizing capacity and thereby lowers the capacity of neutraliz-
ing antibodies to prevent infection [37]. Both formalin and UV
inactivation methods have been used in the production of EV71,
polio and influenza vaccines [26,28,29,38], but the neutralizing
antibody titers obtained with UV inactivated vaccines were report-
edly lower than those obtained with the formalin inactivated vac-
cines [26,28,29,38].
Previous studies have investigated the IgG response to CVBs in
humans and it has been reported that there is a very poor correla-
tion between IgG and CVB neutralizing antibody titers. However, in
assays specifically examining the IgG subclasses, CVB specific IgG1
and IgG3 antibodies were detected [39]. Furthermore, a study
describing human IgG subclass responses to EV71 infections found
that the neutralizing activity of human intravenous immunoglobu-
lin is mainly mediated by the IgG1 subclass [40]. Therefore, we also
studied the quality of the IgG response in the vaccinated mice.
Although the formalin inactivated CVB1 vaccine elicited signifi-
cantly higher neutralizing antibody titers against CVB1 than UV
inactivated vaccine (after three immunizations), the IgG, IgG1
and IgG2a levels were comparable in both groups. Generally, anti-
body responses to soluble protein antigens primarily induce IgG1
which are accompanied by lower levels of the other IgG subclasses
[41]. In the current study, both UV and formalin inactivated CVB1
vaccines induced high Th2-type (IgG1) responses in C57BL/6J mice
characteristic for neutralizing antibody response. Similarly, mono-
valent and bivalent CAV16 and EV71 vaccines were shown to
induce higher levels of IgG1 and IgG2b compared to other IgG sub-
types [42]. Since the IgG subclass responses induced by both vacci-
nes were similar, it remains unclear whether other subclasses were
responsible for the higher level of neutralizing antibodies induced
by the formalin inactivated vaccine.
In conclusion, this study demonstrates that formalin inactivated
CVB1 vaccine induces more robust neutralizing antibody responses
when compared to UV inactivated CVB1 vaccine and provides pro-
5970 M.M. Hankaniemi et al. / Vaccine 37 (2019) 5962–5971tection against viremia after CVB1 infection. We have shown that
formalin treated particles are more resistant, whereas UV treated
particles are less resistant to temperature induced unfolding event
compared to the native virus, and formalin inactivated CVB1 vac-
cine induces predominantly Th2 type antibodies and a protective
level of neutralizing antibodies. These results indicate that forma-
lin inactivated CVBs are promising vaccine candidates for human
clinical trials in the future.
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